|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2011-5-5
|
|
pubmed:abstractText |
To investigate the effect of the estimated highest therapeutic dose of linagliptin (5 mg) on the pharmacokinetics and pharmacodynamics of warfarin, a CYP2C9 substrate.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0946-1965
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
49
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
300-10
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21543033-Adult,
pubmed-meshheading:21543033-Anticoagulants,
pubmed-meshheading:21543033-Area Under Curve,
pubmed-meshheading:21543033-Aryl Hydrocarbon Hydroxylases,
pubmed-meshheading:21543033-Biological Availability,
pubmed-meshheading:21543033-Chromatography, High Pressure Liquid,
pubmed-meshheading:21543033-Dipeptidyl-Peptidase IV Inhibitors,
pubmed-meshheading:21543033-Dose-Response Relationship, Drug,
pubmed-meshheading:21543033-Drug Interactions,
pubmed-meshheading:21543033-Half-Life,
pubmed-meshheading:21543033-Humans,
pubmed-meshheading:21543033-International Normalized Ratio,
pubmed-meshheading:21543033-Male,
pubmed-meshheading:21543033-Middle Aged,
pubmed-meshheading:21543033-Prothrombin Time,
pubmed-meshheading:21543033-Purines,
pubmed-meshheading:21543033-Quinazolines,
pubmed-meshheading:21543033-Software,
pubmed-meshheading:21543033-Stereoisomerism,
pubmed-meshheading:21543033-Tandem Mass Spectrometry,
pubmed-meshheading:21543033-Warfarin,
pubmed-meshheading:21543033-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
|
|
pubmed:affiliation |
Therapeutic Area Metabolism, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
